Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0022 | 1 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0022 | 1 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0022 | 1 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0022 | 1 | 0.5 |
Schistosoma mansoni | ap endonuclease | 0.0022 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0022 | 1 | 0.5 |
Toxoplasma gondii | exonuclease III APE | 0.0022 | 1 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0022 | 1 | 0.5 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0014 | 0.3523 | 0.3523 |
Schistosoma mansoni | ap endonuclease | 0.0022 | 1 | 0.5 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0022 | 1 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0022 | 1 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0014 | 0.3523 | 0.3523 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0022 | 1 | 0.5 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0022 | 1 | 0.5 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0022 | 1 | 1 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0022 | 1 | 0.5 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0022 | 1 | 0.5 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0022 | 1 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0014 | 0.3523 | 0.3523 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0022 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0022 | 1 | 1 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0022 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.